CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Files An 8-K Other Events
Item 8.01
| Other Events. |
On April 19, 2017, CytoSorbents Corporation, a Delaware
corporation (the Company), issued a press release containing a
letter to stockholders and friends of the Company which
discussed, among other topics, the Companys financial health and
material events.
The full text of the press release is filed as Exhibit 99.1 to
this Current Report on Form 8-K.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) Exhibits. | |
| Exhibit No. | Description. |
| 99.1 | CytoSorbents Corporation Press Release, dated April 19, 2017. |
About CYTOSORBENTS CORPORATION (NASDAQ:CTSO)
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others. CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Recent Trading Information
CYTOSORBENTS CORPORATION (NASDAQ:CTSO) closed its last trading session 00.00 at 4.60 with 58,585 shares trading hands.
